-
-
-
-
-
-
-
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/16: (VRCA) (VALN) (ACN) Higher; (IRNT) (SNDX) (ADBE) Lower (more...)
-
-
-
-
-
-
-
After-Hours Stock Movers 09/20: (APRE) (SDC) Higher; (VRCA) (KAR) (LEN) Lower (more...)
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
-
-
-
-
-
-
-
Verrica Pharmaceuticals (VRCA) Provides Regulatory Update on VP-102
-
-
-
-
-
-
-
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

